^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BN-Brachyury

    i
    Other names: BN-Brachyury, MVA-BN brachyury TRICOM vaccine, brachyury/TRICOM, MVA-brachyury-TRICOM, MVA-BN-Brachyury/ FPV-Brachyury, MVA-brachyury-TRICOM vaccine
    Associations

    News

    Trials
    Company:
    Bavarian Nordic
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    over2years
    BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) (clinicaltrials.gov)
    P1b, N=1, Completed, National Cancer Institute (NCI) | Suspended --> Completed | N=65 --> 1 | Trial completion date: Jan 2024 --> Oct 2021 | Trial primary completion date: Jan 2024 --> Oct 2021
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
    |
    HER-2 positive • HR negative
    |
    Kadcyla (ado-trastuzumab emtansine) • Jingzhuda (entinostat) • bintrafusp alfa (M7824) • BN-Brachyury
    over2years
    BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) (clinicaltrials.gov)
    P1b, N=65, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
    |
    HER-2 positive • HR negative
    |
    Kadcyla (ado-trastuzumab emtansine) • Jingzhuda (entinostat) • bintrafusp alfa (M7824) • BN-Brachyury
    over2years
    Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. (PubMed, J Immunother Cancer)
    Intravenous administration of MVA-BN-brachyury-TRICOM vaccine was safe and tolerable. Maximum tolerated dose was not reached. The maximum administered dose was 10 infectious units every 3 weeks for three doses. This dose was selected as the recommended phase 2 dose.
    Clinical • P1 data • Journal
    |
    CD8 (cluster of differentiation 8)
    |
    BN-Brachyury • MVA-BN-Brachyury IV vaccine
    over3years
    BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) (clinicaltrials.gov)
    P1b, N=65, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2022 --> Jan 2024 | Trial primary completion date: Jan 2022 --> Jan 2024
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
    |
    HER-2 positive • HR negative
    |
    Kadcyla (ado-trastuzumab emtansine) • Jingzhuda (entinostat) • bintrafusp alfa (M7824) • BN-Brachyury
    over3years
    BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) (clinicaltrials.gov)
    P1b, N=65, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
    |
    HER-2 positive • HR negative
    |
    Kadcyla (ado-trastuzumab emtansine) • Jingzhuda (entinostat) • bintrafusp alfa (M7824) • BN-Brachyury
    4years
    BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) (clinicaltrials.gov)
    P1b, N=55, Not yet recruiting, National Cancer Institute (NCI)
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
    |
    HER-2 positive • HR negative
    |
    Kadcyla (ado-trastuzumab emtansine) • Jingzhuda (entinostat) • bintrafusp alfa (M7824) • BN-Brachyury